Every day, scientists work toward the advancement of rheumatoid arthritis (RA)treatment. And Dr. C. Michael Stein has made an exciting new discovery that could help these advancements along and predict how specific treatments will work.
Dr. Stein is looking at small molecules that have the potential to cause big problems. His 5-year Arthritis Foundation-funded project, “Extracellular small RNAs in rheumatoid arthritis,” is looking at how small molecules of ribonucleic acid (RNA) in the blood may be markers for different diseases.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. C. Michael Stein
Two different medical groups have separately released recommendations for patients who have osteoporosis – or are at high risk of developing it – outlining the best evidence-based treatment practices to prevent and manage the disease.
Continue reading Two New Sets of Guidelines for Preventing and Treating Osteoporosis
About 1 million knee arthroscopies are performed each year in the United States, at a cost of more than $3 billion. Now, in new guidelines, an international panel of experts has strongly recommended against the surgery for nearly everyone with “degenerative knee disease.” Degenerative knee disease is another way to refer to knee osteoarthritis (OA), and includes degenerative meniscus tears, trouble with knee movement and sudden onset of pain and swelling. The guidelines were published in the journal BMJ in May.
Continue reading Doctors and Patients Say ‘No’ to Arthroscopy for Arthritis
If you suffer from rheumatoid arthritis (RA), Dr. Salah Ahmed’s research project may be just your cup of (green) tea! Dr. Ahmed’s 2014 Innovative Research Grant project, “Mechanism of Mcl-1 regulation in RA by EGCG”, looked at the effects of an anti-inflammatory molecule found in green tea (epigallocatechin-3-gallate or EGCG) on a protein (Mcl-1) found in RA joints.
Continue reading Researchers on the Path to a Cure – Spotlight on Salah Ahmed
Major depression is not uncommon in people with rheumatoid arthritis (RA) – different studies have pegged the number at between 17 percent and 40 percent – but the drugs used to treat RA do little to alleviate depression, according to a systematic review presented at the 2017 British Society for Rheumatology annual conference in Birmingham, United Kingdom.
Continue reading Arthritis Drugs Help Physical Symptoms More Than Disease-Related Depression
What if injured joints could heal themselves before they develop osteoarthritis (OA)? Dr. James Martin’s current 3-year Arthritis Foundation-funded project, “Engineering Endogenous Cartilage Repair,” is trying to do just that- find ways to help joints heal before developing OA.
Dr. Martin and his team use special goats that have defects in areas of the thigh bones and cartilage, just above the knee. This closely mimics knee injuries that are seen in humans. The defects are surgically repaired with a hydrogel matrix that contains two important ingredients: repair cell attractant and growth factor. The repair cell attractant causes repair cells, called chondrogenic progenitor cells (CPCs), to migrate into the hydrogel. CPCs naturally occur in the cartilage. The growth factor, which is time-released over 10 days, causes the CPCs in the hydrogel to multiply and repair the injury with new cartilage.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. James Martin
The Food and Drug Administration (FDA) recently approved the biologic drug sarilumab (Kevzara) for the treatment of rheumatoid arthritis (RA). Sarilumab blocks a protein called interleukin-6 (IL-6), which plays a key role in many inflammatory diseases, including RA. It’s the second IL-6 inhibitor to receive FDA approval for RA; the other, tocilizumab (Actemra), got the nod in 2010.
Continue reading FDA OKs a New Biologic for RA
Trillions of bacteria live in or on your body. There are actually as many bacteria in your body as cells in your body. Fortunately, for most of us, most bacteria that live within us are helpful, not harmful. We call these bacteria commensal bacteria. Dr. Martin Kriegel and his team have been studying these bacteria, and more specifically, a protein that humans and bacteria produce, called Ro60, that plays a role in the development of lupus.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Martin Kriegel
The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis.
Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication.
Continue reading FDA Approves Second Remicade biosimilar
Dr. Rae Yeung believes in collaboration and building networks to solve problems. Her current 3-year Arthritis Foundation-funded project, “Precision Decisions to STOP JIA”, is an example of that. The goal is to develop a tool that will predict treatment response to specific drugs. Dr. Yeung’s study focuses on a group of high-risk children with polyarthritis, one of the most severe forms of childhood arthritis that affects many joints and is difficult to treat.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Rae Yeung